Fig. 2

IL-23 is required for GM-CSF- and TNF-driven arthritic pain and disease development. a mBSA/GM-CSF arthritis (mBSA intra-articular (i.a.) [day 0]; GM-CSF or saline subcutaneous (s.c.) [day 0–2]) and b mBSA/TNF arthritis (mBSA i.a. [day 0]; TNF or saline s.c. [day 0–2]) were induced in WT and Il23p19^−/− mice. Pain (incapacitance meter) and arthritis (histology, day 7) were measured. Data are expressed as mean ± SEM; a, b WT and Il23p19^−/− male mice (mBSA/saline, n = 6; mBSA/GM-CSF and mBSA/TNF, n = 8). For statistical analysis, a two-way ANOVA was used. ^#P < 0.05, ^##P < 0.01, ^###P < 0.001, WT saline vs. WT GM-CSF or TNF. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, WT GM-CSF or TNF vs. Il23p19^−/− GM-CSF or TNF